This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease

This study is currently recruiting participants.
See Contacts and Locations
Verified January 2017 by Dr. SamiUllah, Services Hospital, Lahore
Sponsor:
Information provided by (Responsible Party):
Dr. SamiUllah, Services Hospital, Lahore
ClinicalTrials.gov Identifier:
NCT02782455
First received: March 10, 2016
Last updated: January 26, 2017
Last verified: January 2017
  Purpose
Haemorrhoids are vascular cushions in the anal canal that help in the control of stool. When inflamed they become pathological and may present with protrusion and bleeding. A randomized, triple blind , controlled study will be conducted to compare the efficacy of calcium dobesilate against flavanoids in the management of early haemorrhoidal disease.

Condition Intervention Phase
Hemorrhoids Drug: Flavonoids Drug: CDobi Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease a Randomised Triple Blind Controlled Trial

Resource links provided by NLM:


Further study details as provided by Dr. SamiUllah, Services Hospital, Lahore:

Primary Outcome Measures:
  • Frequency of occurrence of rectal bleeding after usage of drug [ Time Frame: 1 weeks ]
    After the patients will be given the two drugs they will be followed for the frequency of occurrence of rectal bleeding till two weeks


Secondary Outcome Measures:
  • regression of hemorrhoids [ Time Frame: 1 weeks ]
    Patients will under gone per rectal examination and proctoscopy to look for grades of hemorrhoids whether its has decreased or increased.


Estimated Enrollment: 100
Actual Study Start Date: December 2016
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CDobi
Calcium dobesylate is given in this group
Drug: CDobi
Calcium dobesylate is administered
Other Name: dobesilate
Active Comparator: Flavono
Flavonoids are given in this group
Drug: Flavonoids
Daflon is administered
Other Name: Daflon

  Eligibility

Ages Eligible for Study:   13 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Grade I and Grade II hemorrhoids

Exclusion Criteria:

  • CLD
  • colorectal/ anorectal Malignancy
  • self medication
  • local Quack Hakeem medication
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02782455

Contacts
Contact: Usman Ismat Butt, MBBS, FCPS +92-342-4343806 usmanismatbutt@yahoo.com
Contact: Sami Ullah, MBBS,BSc +92-344-4000322 drsamiullahbhatti@gmail.com

Locations
Pakistan
Services Hospital Lahore Recruiting
Lahore, Punjab, Pakistan, 54000
Contact: Sami Ullah, MBBS    +92-344-4000322    drsamiullahbhatti@gmail.com   
Sponsors and Collaborators
Services Hospital, Lahore
Investigators
Study Director: Dr. Waris Farooka, MBBS, FCPS, FRCS, FACS Services Institute of Medical Sciences
  More Information

Responsible Party: Dr. SamiUllah, Postgraduate trainee, Services Hospital, Lahore
ClinicalTrials.gov Identifier: NCT02782455     History of Changes
Other Study ID Numbers: DD
Study First Received: March 10, 2016
Last Updated: January 26, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Hemorrhoids
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases
Calcium, Dietary
Calcium Dobesilate
Bone Density Conservation Agents
Physiological Effects of Drugs
Hemostatics
Coagulants

ClinicalTrials.gov processed this record on June 28, 2017